Karyopharm Therapeutics (KPTI) Total Current Liabilities (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Total Current Liabilities came in at $92.1 million in Q4 2025, little changed YoY from $92.3 million in Q4 2024, and up 5.63% on a QoQ basis from $87.2 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Total Current Liabilities (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Total Current Liabilities data on file, last reported at $92.1 million in Q4 2025.
- Quarterly Total Current Liabilities changed 0.22% year-over-year to $92.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $92.1 million (changed 0.22% YoY) and the FY2025 annual result came in at $92.1 million, changed 0.22% from the prior year.
- Total Current Liabilities grew to $92.1 million in Q4 2025, from $87.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $99.2 million in Q2 2025 to a low of $57.6 million in Q2 2024.
- A 5-year average of $70.8 million and a median of $65.6 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities fell 10.59% — and 2025, when it surged 72.19%.
- Tracing KPTI's Total Current Liabilities over 5 years: stood at $73.7 million in 2021, then fell by 10.59% to $65.9 million in 2022, then advanced by 5.42% to $69.5 million in 2023, then soared by 32.79% to $92.3 million in 2024, then retreated by 0.22% to $92.1 million in 2025.
- The last three Total Current Liabilities figures came in at $92.1 million (Q4 2025), $87.2 million (Q3 2025), and $99.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 134.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.23 Mn |
| Dec 31, 2025 | 92.06 Mn |
| Sep 30, 2025 | 87.16 Mn |
| Jun 30, 2025 | 99.22 Mn |
| Mar 31, 2025 | 90.37 Mn |
| Dec 31, 2024 | 92.26 Mn |
| Sep 30, 2024 | 61.49 Mn |
| Jun 30, 2024 | 57.62 Mn |
| Mar 31, 2024 | 65.34 Mn |
| Dec 31, 2023 | 69.48 Mn |
| Sep 30, 2023 | 62.08 Mn |
| Jun 30, 2023 | 58.93 Mn |
| Mar 31, 2023 | 61.56 Mn |
| Dec 31, 2022 | 65.91 Mn |
| Sep 30, 2022 | 61.76 Mn |
| Jun 30, 2022 | 62.54 Mn |
| Mar 31, 2022 | 66.34 Mn |
| Dec 31, 2021 | 73.72 Mn |
| Sep 30, 2021 | 68.87 Mn |
| Jun 30, 2021 | 58.12 Mn |